Short answer: Oral precursors have more human data. Nicotinamide riboside (NR) and NMN raise blood NAD+ levels in controlled trials and are generally well tolerated.1 For NAD+ given directly, the main human study is an 11-man IV pilot: plasma NAD+ did not rise for the first 2 hours of a 6-hour infusion.2 A 2026 review found no outcome trials of IV or injected NAD+.1
| NAD+ (IV or injection) | Oral NR or NMN | |
|---|---|---|
| What it is | NAD+ itself | Precursors the body converts to NAD+3 |
| Human pharmacokinetic data | One IV pilot, 11 men (8 infused)2 | Several trials, e.g. NR single doses of 100, 300 and 1,000 mg;4 NMN single doses of 100 to 500 mg5 |
| Doses studied | 750 mg IV over 6 hours2 | NR 500 mg twice daily for 6 weeks;6 NMN 250 mg daily for 10 weeks7 |
| Effect on blood NAD+ | No plasma rise for at least the first 2 hours; it was removed from plasma quickly2 | Dose-dependent rise in the blood NAD+ metabolome4 |
| Controlled outcome trials | None found in a 2026 systematic review1 | 28 randomized human studies in that review; outcome results mixed or often null1 |
| Example outcome | Not studied | NMN raised muscle insulin sensitivity in 25 women with prediabetes7 |
| Under-the-skin injection data | No published human half-life | Not applicable |
| Tolerability reported | No adverse events in the IV pilot2 | Generally well tolerated over weeks to months1 |
In the one published human study, 8 healthy men received 750 mg of NAD+ IV over 6 hours (3 controls got none). Surprisingly, plasma NAD+ and its breakdown products did not change for the first 2 hours: the infused NAD+ was removed from the blood quickly and completely. Later, NAD+ and methylnicotinamide appeared in urine.2 The authors say the pattern is consistent with enzymes breaking NAD+ down.2 The study did not measure health outcomes. We found no published human data for NAD+ injected under the skin.
A 2026 systematic review of 33 human studies found oral NR and NMN consistently raise NAD-related markers, but effects on function and health outcomes were mixed and often null.1 No study has compared NAD+ injections with oral precursors head to head. These are study protocols, not personalized advice; confirm any dosing with your prescriber.